Obrixtamig Biosimilar – Anti-DLL3;CD3e mAb – Research Grade

Introduction

Obrixtamig Biosimilar – Anti-DLL3;CD3e mAb is a therapeutic antibody that targets the DLL3 and CD3e proteins. This biosimilar is a research grade version of the original Obrixtamig antibody, which has been developed for the treatment of various cancers.

Structure of Obrixtamig Biosimilar

Obrixtamig Biosimilar is a monoclonal antibody that is produced by recombinant DNA technology. It is composed of two heavy chains and two light chains, each consisting of amino acid sequences that are specific to the target proteins, DLL3 and CD3e. The antibody has a molecular weight of approximately 150 kDa and a half-life of 21 days.

Activity of Obrixtamig Biosimilar

Obrixtamig Biosimilar works by binding to both DLL3 and CD3e proteins simultaneously. This binding prevents the interaction between DLL3 and CD3e, which is crucial for the survival of cancer cells. By blocking this interaction, the antibody inhibits the growth and proliferation of cancer cells, leading to their death.

In addition, Obrixtamig Biosimilar also activates the immune system by binding to CD3e, which is a component of the T-cell receptor complex. This activation triggers the T-cells to attack and destroy cancer cells. This dual mechanism of action makes Obrixtamig Biosimilar a potent therapeutic antibody for cancer treatment.

Therapeutic Target: DLL3 and CD3e

DLL3 and CD3e are two proteins that play crucial roles in cancer development and progression. DLL3 is a Notch ligand that is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors. It is involved in promoting tumor growth and metastasis, making it an attractive therapeutic target.

CD3e, on the other hand, is a protein that is found on the surface of T-cells. It is a component of the T-cell receptor complex, which is responsible for recognizing and attacking foreign or abnormal cells, including cancer cells. By targeting CD3e, Obrixtamig Biosimilar enhances the immune response against cancer cells, leading to their elimination.

Application of Obrixtamig Biosimilar

Obrixtamig Biosimilar has shown promising results in preclinical studies for the treatment of various cancers, including SCLC, neuroblastoma, and other solid tumors. It has also been evaluated in clinical trials for the treatment of SCLC and other DLL3-expressing tumors.

As a research grade antibody, Obrixtamig Biosimilar can be used by scientists and researchers to further study the role of DLL3 and CD3e in cancer biology. It can also be used to develop new therapeutic strategies for cancer treatment.

Conclusion

Obrixtamig Biosimilar – Anti-DLL3;CD3e mAb is a promising therapeutic antibody that targets the DLL3 and CD3e proteins. Its dual mechanism of action makes it a potent agent for the treatment of various cancers. As a research grade antibody, it also has significant applications in cancer research. Further studies and clinical trials are needed to fully explore the potential of this biosimilar in cancer treatment.